Poly Medicure Limited (POLYMED) fair value: what the stock is really worth
We calculate from audited financials what Poly Medicure Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Poly Medicure Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range ₹662.56 – ₹3,123 · fair‑value band ₹729.40 – ₹1,216 · the ₹1,739 price screens above the ₹972.52 fair value. Dashed = 300-day average. As of Sep 13, 2026.
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally.
Show more
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular access products; oncology products; diagnostics products, such as blood collection tubes, safety blood collection set, blood collection needles, and standard needle holder. In addition, the company offers transfusion system products, including blood bags, blood administration set, and others; anesthesia and respiratory care products, comprising variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, aerosol therapy masks, ventilator circuits, suction catheters, spinal needle, polyciser, oxygen catheter, nebulizer compressor system, twin bore nasal oxygen cannula mucus extractor, HME filter, oro-pharyngeal airways, endotracheal tubes, catheter mount, and brain circuit; urology products, including urine collection bags, leg bag set, irrigation sets, foley balloon and urine drainage catheters, and urine collection bags with measured volume meters; wound drainage; and gastroenterology products. The company was incorporated in 1995 and is based in New Delhi, India.
Stock analysis
Poly Medicure Limited (POLYMED) currently trades at ₹1,739, while our model-based Fair Value estimate is ₹972.52, implying the stock looks roughly 78.8% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹808.05 per share, and 0 of the 17 models we run sit above the ₹1,739 price.
Bear case: the Asset-Based group reads lowest at ₹205.32, and 17 of the 17 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹729.40 (bear) to ₹1,216 (bull), the price of ₹1,739 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Poly Medicure Limited reported revenue of ₹18.8B in FY2026 versus ₹9.2B in FY2022, a compound +19.4%/yr. Reported net income was ₹3.2B in FY2026, compounding +21.8%/yr from FY2022.
Key figures
Market cap ₹176B (≈ $1.9B) · P/E ratio 54.6 · P/S ratio 9.37 · EPS (TTM) ₹31.82 · Dividend yield 0.2% · Net margin 17.2% · Return on equity 10.9% · Return on assets (EBIT) 24.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −44%, POLYMED screens richer than that median.
Fair Value models
Bear ₹729.40Fair Value ₹972.52Bull ₹1,216
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 5 months old). Earnings retained since then (₹12.96 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.0%
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.8%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+16.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+15.8%
Dividend (yield on the price)0.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.16% vs 18%, steady
Profit margin 2006 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 17%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 202 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside−43% · Below median
Profitability
Return on equity (TTM)11% · Above median
Return on assets6% · Above median
Net margin (TTM)17% · Top 25%
Operating margin (TTM)14% · Above median
Growth and dividend
Revenue growth21% · Top 25%
Dividend yield (TTM)0.2% · Bottom 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (TTM)54.6× · Priciest 25%
P/B5.66× · Priciest 25%
P/S (TTM)9.37× · Priciest 25%
EV/EBITDA39.7× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 16
FUTURE (revenue growth)100· sector 24
PAST (return on equity)43· sector 25
HEALTH (low debt)99· sector 96
DIVIDEND (yield)4· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Poly Medicure Limited (POLYMED) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ₹972.52 versus a price of ₹1,739, about −44% upside (overvalued).
What is the fair value of POLYMED?
Our model-based fair value for Poly Medicure Limited is ₹972.52 (as of Sep 13, 2026), built from audited fundamentals. The current price: ₹1,739.
What is the quality score of POLYMED?
Poly Medicure Limited has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Poly Medicure Limited (POLYMED)?
Our model-based price target is the fair value of ₹972.52 (as of Sep 13, 2026) from 17 valuation models. Cautious scenario ₹729.40, optimistic scenario ₹1,216. It is a calculation from audited fundamentals, not an analyst target.
What is the Poly Medicure Limited stock forecast for 2026?
Our models put fair value at ₹972.52, about −44% upside versus a price of ₹1,739 (overvalued). Cautious scenario ₹729.40, optimistic scenario ₹1,216. The calculation is refreshed regularly with new filings.
What is the revenue of Poly Medicure Limited (POLYMED)?
Poly Medicure Limited reported trailing-twelve-month revenue of about ₹18.8B (latest available figure, as of Sep 13, 2026).
Does Poly Medicure Limited pay a dividend?
Poly Medicure Limited currently shows a dividend yield of about 0.20% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Poly Medicure Limited (POLYMED)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Poly Medicure Limited it is ₹972.52 per share (as of Sep 13, 2026), against a price of ₹1,739. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Poly Medicure Limited stock overvalued or undervalued in 2026?
As of Sep 13, 2026, POLYMED trades above its calculated fair value: price ₹1,739, fair value ₹972.52, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of POLYMED?
No. The price is what the market pays today (₹1,739); the fair value is what the company's own numbers justify (₹972.52). For Poly Medicure Limited the two are ₹765.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is Poly Medicure Limited worth?
The market values Poly Medicure Limited at about ₹176B (market capitalisation, as of Sep 13, 2026). Per share that is ₹1,739; our models calculate a fair value of ₹972.52 per share.
What do the bullish and bearish scenarios say about POLYMED?
Our models span a range for Poly Medicure Limited: cautious scenario ₹729.40, base ₹972.52, optimistic ₹1,216 per share (as of Sep 13, 2026, price ₹1,739). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of POLYMED?
Poly Medicure Limited trades at a price-to-earnings ratio of 54.6 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹972.52 is built from several models across several years. Other multiples: P/B 5.7, P/S 9.4, EV/EBITDA 39.7.
How solid is the balance sheet of Poly Medicure Limited (POLYMED)?
Balance-sheet figures for Poly Medicure Limited (as of Sep 13, 2026): return on equity 10.9%, debt of 0.02 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is POLYMED from its 52-week high?
Poly Medicure Limited trades at ₹1,739, about 23% below its 52-week high of ₹2,269 and 47% above the low of ₹1,182 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ₹972.52 is for.
Which stocks are comparable to Poly Medicure Limited?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Poly Medicure Limited stock attractive at the current price?
The data as of Sep 13, 2026: price ₹1,739, calculated fair value ₹972.52 (−44%), Quality Score 43/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of POLYMED calculated?
We run Poly Medicure Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹972.52, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Poly Medicure Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Poly Medicure Limited right now?
The price sits above even our optimistic bull case (₹1,216). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
Where does the earnings growth of Poly Medicure Limited (POLYMED) come from?
Earnings per share at Poly Medicure Limited grew +19.4 % a year from 2015 to 2026. Broken into its drivers: revenue per share +14.9 %, EBIT margin −2.1 %, tax rate +0.3 %, residual (interest, one-offs) +5.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Poly Medicure Limited
How large is the market capitalisation of Poly Medicure Limited (POLYMED)?
The market capitalisation of Poly Medicure Limited is ₹176B (≈ $1.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Poly Medicure Limited (POLYMED)?
The price-to-sales ratio of Poly Medicure Limited is 9.37 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Poly Medicure Limited (POLYMED)?
Earnings per share at Poly Medicure Limited are ₹31.82 (price ÷ EPS = P/E 54.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Poly Medicure Limited (POLYMED)?
The dividend yield of Poly Medicure Limited is 0.2% (payout 11.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Poly Medicure Limited (POLYMED)?
The net margin of Poly Medicure Limited is 17.2% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Poly Medicure Limited (POLYMED)?
The return on equity (ROE) of Poly Medicure Limited is 10.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Poly Medicure Limited (POLYMED)?
On an EBIT basis the return on assets of Poly Medicure Limited is 24.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Poly Medicure Limited (POLYMED)?
The operating margin of Poly Medicure Limited is 13.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Poly Medicure Limited (POLYMED)?
Revenue at Poly Medicure Limited is growing +21.3% versus a year earlier (3y avg +18.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Poly Medicure Limited (POLYMED)?
Earnings per share at Poly Medicure Limited are growing −26.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Poly Medicure Limited (POLYMED) generate?
The free cash flow of Poly Medicure Limited is −₹602M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Poly Medicure Limited (POLYMED) carry?
The net debt of Poly Medicure Limited is ₹2.7B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Poly Medicure Limited in the live analysis
One click puts Poly Medicure Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
